Insurance coverage for the treatment of patients with chronic renal insufficiency.<br /> Adoption of economic assessment by the Institute of Social Insurance (IKA)
Journal Title: Αρχεία Ελληνικής Ιατρικής - Year 2009, Vol 26, Issue 5
Abstract
Chronic kidney disease (CKD) constitutes a multidimensional problem for both the patients but also the state. The number of patients with final stage chronic kidney disease (FSCKD) has reached dimensions of epidemic in the entire world, while, according to recent data, Greece ranks in the 8th place in a global comparison of prevalence of patients in treatment of substitution of renal function (RRT), with this pool of patients increasing by 5-7% annually. This increase translates to an enormous economic strain for the funds of social insurance on the one hand but also with regards to the quality of life of patients and their families. Indicatively, it is estimated that IKA alone annually spends 37,000 € for each patient in renal replacement treatment. One of the problems presented early in the development of disease (stages 3 and 4) is secondary hyperparathyroidism which is linked to the increase of complications and resulting hospitalisations of patients, and accordingly further increased costs for both the patient and the system. "Z" is linked to the prevention and treatment of secondary hyperparathyroidism in patients with CKD stages 3, 4 and 5 and is also linked to the increase of survival and delay of procession to RRT. OBJECTIVE The aim of the present study was to appreciate the effectiveness, the efficiency and the benefit that will result from the assumption of cost of contribution (25%) to the expense of the drug from IKA. METHOD The data used are epidemiologic (prevalence of stages CKD, RRT, and secondary hyperparathyroidism in Greece), the cost caused by patients to the system, as well as the social cost patients experience, while data are mentioned relative to the effectiveness of "Z", and the, according to international published studies, proven economic benefits from its use. RESULTS-CONCLUSIONS We reached the conclusion that if IKA was to bear part of the cost contribution (additional annual expense 10,647,120 €) would in the long term result in a 39,926,700 € benefit due to the delay of a percentage of patients entering stage 5.
Authors and Affiliations
K. SOULIOTIS, M. PAPAVASILOPOULOU, C. KONSTANTINIDOU, A. SPANAKIS
Keywords
Related Articles
- EP ID EP102364
- DOI -
- Views 51
- Downloads 0
A study of hereditary motor and sensory neuropathies (Charcot-Marie-Tooth disease) in the Greek population
OBJECTIVE Molecular analysis of hereditary motor and sensory neuropathy, Charcot-Marie-Tooth disease (CMT) in the Greek population. METHOD In total, 327 Greek index patients investigated for possible hereditary motor...
Απόστημα του προσπονδυλικού διαστήματος μετά από ένεση κορτικοστεροειδών<br />
AML, M5 type, -Beau Lines
A 35-year-old woman presented to the outpatient dep artment because of fever during the last fifteen days and symptoms from the upper respiratory tract. She was treated with trimethoprim/ sulphamethoxazole and the fe...
Antiviral drugs for the treatment of HIV-seropositive patients:<br /> nephrotoxicity and dose adjustments in renal insufficiency
Patients with HIV infection and HIV-related opportunistic infections and malignancies are treated extensively with a broad spectrum of drugs. The introduction of new antiretroviral drugs, such as protease inhibitors and...
Recombinant polypeptides of the acetylcholine receptor in the development<br /> of an antigen-specific therapy for myasthenia gravis through the immunoadsorption <br /> of anti-receptor antibodies from myasthenic patients
OBJECTIVE The pathology of the autoimmune disease myasthenia gravis is largely explained by autoantibodies produced against the human muscle acetylcholine receptor. Plasmapheresis offers a significant therapeutic option...